Log in to search using one of your social media accounts:

 

Bake-Off ’s Chris Geiger writes moving account of cancer
The Great British Bake Off's latest eliminated contestant was diagnosed with non-Hodgkin lymphoma at just 24 years old after doctors dismissed his breathlessness as stress for eight months. (Source: the Mail online | Health)
Source: the Mail online | Health - September 6, 2017 Category: Consumer Health News Source Type: news

Chi-Med begins Phase I trial of lymphoma drug in China
Hutchison China MediTech (Chi-Med) has begun a Phase I clinical trial of its therapeutic candidate HMPL-689 to treat patients with non-Hodgkin lymphoma in China. (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review for Roche ’s Gazyva in previously untreated follicular lymphoma
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva® (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma, one of the most common blood cancers among adults. Follicular lymphoma, a slow-growing (indolent) form of non-Hodgkin lymphoma, is incurable and characterized by cycles of remission and relapse. (Source: Roche Investor Update)
Source: Roche Investor Update - August 28, 2017 Category: Pharmaceuticals Source Type: news

Significant Portion of Pediatric NHL Cases Occur in Transplant Recipients
Pediatric solid organ transplant recipients account for about 3% of diagnosed pediatric non-Hodgkin lymphoma cases in the United States. (Source: CancerNetwork)
Source: CancerNetwork - August 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Women having children over 30 give them higher cancer risk
Parents over 35 are linked to an increased risk of leukaemia diagnoses, a Los Angeles study has found. This age group are also linked with higher rates of non-Hodgkin lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - August 2, 2017 Category: Consumer Health News Source Type: news

US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
THE WOODLANDS, Texas and CAMBRIDGE, Mass. (August 1, 2017)  - Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US Oncology Research, one of the nation’s largest networks of independent, community-based oncology practices dedicated to ad... (Source: McKesson News)
Source: McKesson News - August 1, 2017 Category: Information Technology Source Type: news

Nigeria: Nigerian Doctor, Donald Nwosu Battles Deadly Cancer
[This Day] As public health physician, Donald Nwosu battles a rare type of cancer, Non-Hodgkins Lymphoma, Martins Ifijeh chronicles his fight to overcome the deadly disease, adding that he urgently needs help in order to survive it (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 20, 2017 Category: African Health Source Type: news

Monsanto Denies Glyphosate Exposure Could Have Caused Man's Cancer
SAN FRANCISCO - Monsanto Co. on June 16 filed its answer to one of the complaints in the multidistrict litigation for Roundup products, in which it denied that exposure to its product, which contains glyphosate, could have caused the plaintiff's alleged non-Hodgkin lymphoma (NHL) (In re: Roundup Products Liability Litigation, No. 2741 MDL, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 6, 2017 Category: Medical Law Source Type: news

Roche ’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2017 Category: Pharmaceuticals Source Type: news

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 29, 2017 Category: American Health Source Type: news

Loan Woll who had stillborn learns she has stage 4 cancer
Loan Woll, 31, gave birth to her stillborn son Finnick in Ontario, Canada, on January 14. She was told her stage 4 non-Hodgkin lymphoma cancer had caused the death of her child. (Source: the Mail online | Health)
Source: the Mail online | Health - June 27, 2017 Category: Consumer Health News Source Type: news

Monsanto Spin Doctors Target Cancer Scientist In Flawed Reuters Story
In a well-orchestrated and highly coordinated media coup, Monsanto Co. and friends this week dropped a bombshell on opponents who are seeking to prove that the company’s beloved Roundup herbicide causes cancer. A widely circulated story published June 14 in the global news outlet Reuters (for which I formerly worked) laid out what appeared to be a scandalous story of hidden information and a secretive scientist, “exclusive” revelations that the story said could have altered a critical 2015 classification that associated Monsanto’s Roundup to cancer and triggered waves of lawsuits against Monsanto. ...
Source: Science - The Huffington Post - June 16, 2017 Category: Science Source Type: news

FDA accepts priority review for Kite Pharma ’s refractory aggressive NHL treatment
The US Food and Drug Administration (FDA) has accepted priority review for cell therapy company Kite Pharma ’s biologics licence application (BLA) for axicabtagene ciloleucel to treat patients with refractory aggressive non-Hodgkin lymphoma (NHL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 29, 2017 Category: Pharmaceuticals Source Type: news

What You Need to Know if You Have Breast Implants
There is no need to remove implants if you have no problems, but if you have swelling, fluid buildup, lumps or asymmetry you should see a doctor. (Source: NYT Health)
Source: NYT Health - May 14, 2017 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Breasts Non-Hodgkin's Lymphoma Surgery and Surgeons Source Type: news

A Shocking Diagnosis: Breast Implants ‘ Gave Me Cancer ’
A rare cancer of the immune system, linked to implants, has had devastating effects on women, many of whom had reconstructive surgery after breast cancer. (Source: NYT Health)
Source: NYT Health - May 14, 2017 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Allergan Inc Immune System Surgery and Surgeons Cancer Non-Hodgkin's Lymphoma Breasts Plastic Surgery Source Type: news

Man: Case Against Monsanto Should Not Be Stayed Pending Ruling On MDL Transfer
ST. LOUIS - A Missouri man who sued Monsanto Co. for allegedly causing his non-Hodgkin lymphoma (NHL) through the manufacturing and distribution of glyphosate, the active ingredient in Roundup, on April 25 filed a brief in Missouri federal court arguing that the district court should reconsider the stay it issued pending a determination on transfer to the multidistrict litigation because the case does not need to be transferred (Steve Salvaggio, et al. v. Monsanto Company, et al., No. 17-1113, E.D. Mo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - May 2, 2017 Category: Medical Law Source Type: news

Gov. Larry Hogan on Maryland's life sciences cluster: 'This mission is a very personal one to me'
When Gov. Larry Hogan stepped up to address a crowd of more than 1,000 life sciences executives and entrepreneurs on Wednesday, he couldn ’t help but take the moment to remember his own brush with their work. In 2015, the then-new governor was diagnosed with non-Hodgkin's lymphoma. More than a year and a half since reaching remission, he is still cancer free, he told the BioHealth Capital Region forum. The two-day conference at Me dImmune's headquarters in Gaithersburg was held to promote collaboration… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 20, 2017 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

Gov. Larry Hogan on Maryland's life sciences cluster: 'This mission is a very personal one to me'
When Maryland Gov. Larry Hogan stepped up to address a crowd of more than 1,000 life sciences executives and entrepreneurs on Wednesday, he couldn ’t help but take the moment to remember his own brush with their work. In 2015, the then-new governor was diagnosed with non-Hodgkin's lymphoma. More than a year and a half since reaching remission, he is still cancer free, he told the BioHealth Capital Region forum. The two-day conference at Me dImmune's headquarters in Gaithersburg was held to promote… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 19, 2017 Category: American Health Authors: Tina Reed Source Type: news

Gov. Larry Hogan on Maryland's life sciences cluster: 'This mission is a very personal one to me'
When Maryland Gov. Larry Hogan stepped up to address a crowd of more than 1,000 life sciences executives and entrepreneurs on Wednesday, he couldn ’t help but take the moment to remember his own brush with their work. In 2015, the then-new governor was diagnosed with non-Hodgkin's lymphoma. More than a year and a half since reaching remission, he is still cancer free, he told the BioHealth Capital Region forum. The two-day conference at Me dImmune's headquarters in Gaithersburg was held to promote… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 19, 2017 Category: Biotechnology Authors: Tina Reed Source Type: news

Judge Remands PCB Case Against Monsanto, Says Removal Was Improper
ST. LOUIS - A federal magistrate judge in Missouri on April 10 remanded a lawsuit brought by residents who contend that polychlorinated biphenyls (PCBs) manufactured by Monsanto Co. are liable for their development of non-Hodgkin lymphoma (NHL) on grounds that it was improperly removed to federal court (Kent N. Burford v. Monsanto Co., et al., No. 16-536, E.D. Mo.; 2017 U.S. Dist. LEXIS 54293). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - April 18, 2017 Category: Medical Law Source Type: news

CAR T-Cell Therapy Yields High Response Rate in Aggressive Lymphoma
This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 7, 2017 Category: Cancer & Oncology Authors: Frederick Locke, MD Tags: Conferences/AACR 2017 Videos Hematologic Malignancies Source Type: news

Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma
This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2017 Category: Cancer & Oncology Authors: Martin Dreyling, MD Tags: Videos Hematologic Malignancies Source Type: news

Moms Exposed To Monsanto Weed Killer Means Bad Outcomes For Babies
Concerns about the world’s most widely used herbicide are taking a new twist as researchers unveil data that indicates pervasive use of Monsanto Co.’s weed killer could be linked to pregnancy problems. Researchers looking at exposure to the herbicide known as glyphosate, the key ingredient in Monsanto’s Roundup-branded herbicides, said they tested and tracked 69 expectant mothers and found that the presence of glyphosate levels in their bodily fluids correlated with unfavorable birth outcomes. The research is still in preliminary stages and the sample size is small, but the team is scheduled to present th...
Source: Healthy Living - The Huffington Post - April 4, 2017 Category: Consumer Health News Source Type: news

Monsanto Denies That Exposure To Glyphosate Causes Cancer
ST. LOUIS - Monsanto Co. on March 28 filed an answer in Missouri federal court denying that any exposure to its herbicide Roundup, with its active ingredient glyphosate, can cause non-Hodgkin lymphoma (NHL) or other cancers, as alleged by numerous individuals who have used Roundup (Steve Salvaggio, et al. v. Monsanto Company, et al., No. 17-1113, E.D. Mo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - April 4, 2017 Category: Medical Law Source Type: news

Bayer's copanlisib meets primary endpoint in Phase II trial to treat iNHL
German chemical and lifesciences firm Bayer has reported positive results from the Phase II CHRONOS-1 clinical trial of copanlisib for the treatment of indolent non-Hodgkin's lymphoma (iNHL) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - April 3, 2017 Category: Pharmaceuticals Source Type: news

Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
SANTA MONICA, Calif. March 31, 2017 --(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has completed the rolling submission with the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 31, 2017 Category: Drugs & Pharmacology Source Type: news

Spencer gets back on the court after cancer
For much of his 17 years, Spencer Riley has lived to play basketball. This winter, his favorite sport helped the teenager get back to life. Riley was diagnosed with non-Hodgkin lymphoma in 2016 and treated at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center that summer. He underwent an intensive three-month treatment cycle: one week of inpatient chemotherapy at Boston Children’s Hospital, two weeks of recuperation at home, and then back to Boston Children’s. While occasionally well enough to go on family outings, he was still too weak to shoot or even dribble a basketball. But the game was ...
Source: Thrive, Children's Hospital Boston - March 29, 2017 Category: Pediatrics Authors: Saul Wisnia Tags: Diseases & Conditions Our Patients’ Stories Dana-Farber/Boston Children's Cancer and Blood Disorders Center Dr. Dan Benedetti non-Hodgkin lymphoma Source Type: news

Woman: Monsanto's 'Fraud' Caused Her To Develop Cancer From Exposure To Glyphosate
ST. LOUIS - A Missouri woman on March 17 filed a lawsuit against Monsanto Co. in Missouri federal court, alleging that the company committed scientific fraud and is liable for her development of non-Hodgkin lymphoma (NHL), which was the result of exposure to glyphosate, the active ingredient in the herbicide Roundup (Linda Crane v. Monsanto Co., No. 17-982, E.D. Mo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - March 28, 2017 Category: Medical Law Source Type: news

Thousands of people now have non-Hodgkin's Lymphoma due to glyphosate (Roundup) exposure, warns legal firm that's suing Monsanto
(Natural News) Will Monsanto finally get what they deserve for their crimes against humanity? The Miller Firm hopes to bring the corporate giant to their knees by pursuing a lawsuit that shows Roundup can cause non-Hodgkin’s lymphoma and multiple myeloma. And perhaps, in their pursuance of this litigation, the EPA will be taken down, too.... (Source: NaturalNews.com)
Source: NaturalNews.com - March 23, 2017 Category: Consumer Health News Source Type: news

FDA Links Breast Implants To Cases Of Rare Blood Cancer
The agency announced that at least nine women have died from a form of non-Hodgkin's lymphoma associated with the surgery. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 22, 2017 Category: Pharmaceuticals Authors: Janet Burns, Women at Forbes Source Type: news

Monsanto tried to hide evidence of glyphosate (RoundUp) causing Non-Hodgkin's Lymphoma: COURT DOCUMENTS
(Natural News) Court documents released on March 13th show that Monsanto colluded with the EPA to bury scientific evidence linking its glyphosate product (RoundUp) to cancer in humans (specifically, Non-Hodgkin’s Lymphoma). Glyphosate.news has published the full text of the court document “Motion to Compel Deposition of Jess Rowland.” Also published on Glyphosate.news is this heartbreaking... (Source: NaturalNews.com)
Source: NaturalNews.com - March 15, 2017 Category: Consumer Health News Source Type: news

Kite's shares fly high after cancer drug clears main study goal
(Reuters) - Kite Pharma Inc said on Tuesday its experimental CAR T-cell therapy, which helps the immune system fight cancer, was highly effective in treating aggressive non-Hodgkin's lymphoma, meeting the main goal of a key study. (Source: Reuters: Health)
Source: Reuters: Health - February 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Gene Therapy Shows Promise for Aggressive Lymphoma
TUESDAY, Feb. 28, 2017 -- An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy's developers report. Thirty-six percent of over 100 very ill lymphoma patients... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 28, 2017 Category: Journals (General) Source Type: news

UNC Lineberger launches innovative cellular immunotherapy program
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center has opened two cellular immunotherapy trials. The early-stage CAR-T trials are for patients with either Hodgkin lymphoma or non-Hodgkin lymphoma, who lack other treatment options or are at high risk of their disease returning. Researchers are working to open trials for other cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 28, 2017 Category: Global & Universal Source Type: news

3 Sets Of Plaintiffs: Monsanto Concealed Carcinogenicity Of Glyphosate
SAN FRANCISCO - A California couple on Feb. 9 filed a lawsuit against Monsanto Co. in California federal court, alleging that the husband of the couple has contracted non-Hodgkin lymphoma from exposure to the company's herbicide Roundup, which contains that active ingredient glyphosate (Joseph E. Shipley, et al. v. Monsanto Co., No. 17-651, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - February 21, 2017 Category: Medical Law Source Type: news

Israeli, Palestinian researchers cooperate to find risks for B cell non-hodgkin lymphoma
(The Hebrew University of Jerusalem) Most epidemiological studies of Non-Hodgkin's Lymphoma (NHL) have been carried out in North American and European populations, with very few focusing on B-cell NHL in Middle Eastern populations. Now, Israeli and Palestinian researchers have conducted a large scale epidemiological study examining risk factors for B-NHL and its sub-types in the Israeli and Palestinian populations, finding some risk factors common to both groups, and some that are unique to only one population. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2017 Category: Cancer & Oncology Source Type: news

Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment
OSLO (Reuters) - Norwegian biotech newcomer Nordic Nanovector , which seeks ways to treat blood-related cancers, says other companies are showing interest in buying the firm. (Source: Reuters: Health)
Source: Reuters: Health - February 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

4 More Cancer Cases Against Monsanto Transferred To Roundup MDL
WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation on Jan. 31 issued a conditional transfer order sending four glyphosate injury cases to the multidistrict litigation in the U.S. District Court for the Northern District of California, adding still more cases in which the plaintiffs allege that their exposure to the Roundup herbicide caused them to develop non-Hodgkin lymphoma (NHL) (In Re: Roundup Products Liability Litigation, No. 2741, JPMDL). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - February 9, 2017 Category: Medical Law Source Type: news

U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
NORTH CHICAGO, Ill., Jan. 19, 2017 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) for the treatment of patient... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, marginal zone lymphoma, Non-Hodgkin's Lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2017 Category: Pharmaceuticals Source Type: news

Monsanto Misrepresented Safety Of Roundup, Man Says; Exposure Resulted In Cancer
DENVER - A Colorado man on Jan. 6 filed a lawsuit against Monsanto Co. in the U.S. District Court of the District of Colorado, alleging that he developed non-Hodgkin lymphoma (NHL) from exposure to glyphosate, the active ingredient in the herbicide Roundup, and that the company knowingly misrepresented that the product was safe (John Holm v. Monsanto Co., No. 17-56, D. Colo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - January 18, 2017 Category: Medical Law Source Type: news

Monsanto Co. Denies Exposure To Roundup Could Have Caused Man's 'Alleged' Cancer
SAN FRANCISCO - Monsanto Co. on Jan. 6 filed an answer in one of the cases that is part of the multidistrict litigation pending in California federal court related to injuries allegedly caused by Roundup, denying that exposure to the herbicide "did or could have caused" the plaintiff's "alleged" non-Hodgkin's lymphoma (NHL) (In Re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - January 18, 2017 Category: Medical Law Source Type: news

Prolonged exposure to work-related stress thought to be related to certain cancers
For men, prolonged exposure to work-related stress has been linked to an increased likelihood of lung, colon, rectal, and stomach cancer and non-Hodgkin lymphoma. This is the first study to assess the link between cancer and work-related stress perceived by men throughout their working life. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 17, 2017 Category: Science Source Type: news

Prolonged exposure to work-related stress thought to be related to certain cancers
(Institut national de la recherche scientifique - INRS) For men, prolonged exposure to work-related stress has been linked to an increased likelihood of lung, colon, rectal, and stomach cancer and non-Hodgkin lymphoma. The findings are among the results obtained by researchers at INRS and Universit é de Montr é al who conducted the first study to assess the link between cancer and work-related stress perceived by men throughout their working life. The research results were recently published in Preventive Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 17, 2017 Category: Global & Universal Source Type: news

VA ’s Rule Establishes a Presumption of Service Connection for Diseases Associated with Exposure to Contaminants in the Water Supply at Camp Lejeune
The U.S. Department of Veterans Affairs (VA) announced that it has established a presumption of service connection for eight diseases that may be associated with exposure to contamination in the water supply at Camp Lejeune in North Carolina from August 1, 1953 to December 31, 1987. This will make it easier for veterans to receive the care and benefits they need. The eight diseases are adult leukemia, aplastic anemia and other myelodysplatic syndromes, bladder, kidney, or liver cancer, multiple myeloma, non-Hodgkin's lymphoma, and Parkinson's disease. (Source: News stories via the Rural Assistance Center)
Source: News stories via the Rural Assistance Center - January 13, 2017 Category: Rural Health Source Type: news

Mail Sudthiya from Thailand with tumour given money for food and drugs by monk
Mail Sudthiya, from Thailand, suffers from Non-Hodgkin lymphoma. A monk, known as Bhin, donated money to provide her food and medication in her final days after she couldn't afford treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - January 11, 2017 Category: Consumer Health News Source Type: news

Glyphosate Injury Case Related To Monsanto's Roundup Moved To MDL
WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation on Dec. 21 transferred another glyphosate injury lawsuit to the multidistrict litigation in the U.S. District Court for the Northern District of California, adding another case in which the plaintiff alleges that his exposure to the Roundup herbicide caused him to develop non-Hodgkin's lymphoma (NHL) (In Re: Roundup Products Liability Litigation, No. 2741, JPMDL). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - January 4, 2017 Category: Medical Law Source Type: news

Outlook for 2017: Myeloma, Lymphoma, and MPNs
This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloproliferative neoplasms. (Source: CancerNetwork)
Source: CancerNetwork - December 23, 2016 Category: Cancer & Oncology Authors: Amrita Y. Krishnan, MD David Snyder, MD Robert Chen, MD Tanya Siddiqi, MD Tags: Conferences/Hematologic Malignancies Year in Review 2016 Source Type: news

Man Sues Monsanto, Says His Cancer Was Caused By Exposure To Roundup
ST. LOUIS - A man who has been diagnosed with non-Hodgkin's lymphoma (NHL) filed a lawsuit in Missouri federal court on Dec. 15, alleging that Monsanto Co. is liable for his injuries as the manufacturer of glyphosate, the active ingredient in the herbicide Roundup, which he claims is "defective, dangerous to human health, unfit and unsuitable to be marketed and sold in commerce, and lacked proper warnings and directions as to the dangers associated with its use" (Michael Dowling v. Monsanto Company, No. 16-1935, E.D. Mo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - December 21, 2016 Category: Medical Law Source Type: news

Mayo Clinic first in U.S. to offer lymphoma genomic diagnostic test for patients
PHOENIX ? Mayo Clinic has created a genetic test to help guide diagnosis and treatment of patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin?s lymphoma. The Lymph2Cx test helps determine where the lymphoma started, assigning ?cell-of-origin? groups using a 20-gene expression-based assay. It is the first test to go into the [...] (Source: Mayo Clinic Business News)
Source: Mayo Clinic Business News - December 14, 2016 Category: Pharmaceuticals Source Type: news

CAR T-Cell Immunotherapy for Aggressive NHL Effective, Feasible in Real-World Setting
The use of anti-CD19 chimeric antigen receptor T cells induced a nearly sixfold higher rate of complete response compared with historical outcomes in patients with refractory, aggressive non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 14, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASH 2016 Leukemia & Lymphoma News Source Type: news